Chimeric antigen receptor (CAR) T cells have limited efficacy against solid tumors including neuroblastoma.
Here, we evaluated whether low-dose radiation delivered by radiopharmaceutical therapy (RPT), known to potentiate immune checkpoint inhibitors, can synergize with CRISPR-edited GD2
